Copyright

(c) 2010-2025 Jon L Gelman, All Rights Reserved.

Friday, March 5, 2010

Possible Vaccine for Mesothelioma

A vaccine has been demonstrated as safe for potential use against mesothelioma. The research, conducted by Netherlands scientists was reported in an advance publication of  the American Journal of Respiratory and Critical Care.


The scientists concluded that, This study demonstrated that autologous tumor lysate-pulsed dendritic cell-based therapy is feasible, well-tolerated, and capable of inducing immunological response to tumor cells in mesothelioma patients."

Mesothelioma is a rare and fatal  malignant tumor associated with asbestos exposure. Asbestos was mined and its fiber used for fire-retartant insulation properties. Asbestos use has resulted in an a legacy of illness and death decades following exposure because of the latent and progressive nature of the disease. Asbestos production is not yet banned in the United States.

Findings indicated that, "Administration of dendritic cells pulsed with autologous tumor lysate in mesothelioma patients was safe with moderate fever as the only side effect.There were no grade 3 or 4 toxicities associated with the vaccines or any evidence of autoimmunity. Local accumulations of infiltrating T cells were found at the site of vaccination. The vaccinations induced distinct immunological responses to KLH, both in vitro and in vivo. Importantly, after three vaccinations, cytotoxic activity against autologous tumor cells was detected in a subgroup of patients."


The Study: J. P Hegmans, J. D. Veltman, M. E Lambers, I. J. M. de Vries, C. G. Figdor, R. W Hendriks, H. C. Hoogsteden, B. N. Lambrecht, and J. G. Aerts , Consolidative Dendritic Cell-Based Immunotherapy Elicits Cytotoxicity Against Malignant Mesothelioma, Am. J. Respir. Crit. Care Med. 2010 0: 200909-1465OCv1-


More articles about this research:
Health Day: Vaccine for Asbestos-Related Cancer Looks Safe. In tests, novel immunotherapy appears to combat mesothelioma tumors.